Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN S YANG

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1053370353
CMS profile
274834
Location
ALBANY, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$1,885.69

81 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,786.69 80
Education $99.00 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN S YANG

NPI 1053370353 · CMS profile ID 274834

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

ALBANY, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1053370353?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN S YANG, NPI 1053370353, CMS profile ID 274834. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1053370353?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). STEVEN S YANG, NPI 1053370353, CMS profile ID 274834. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1053370353?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
STEVEN S YANG, NPI 1053370353, CMS profile ID 274834, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1053370353?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

81 matching records · $1,885.69 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 81 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–81 of 81.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $32.8206/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886733991 CMS
Celgene Corporation $5.7005/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932546295 CMS
Celgene Corporation $4.4905/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932546297 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.0905/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959475305 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.8205/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955883243 CMS
Celgene Corporation $11.3005/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932546291 CMS
Janssen Biotech, Inc. $28.9905/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886733967 CMS
ABBVIE INC. $27.4304/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893244859 CMS
Takeda Pharmaceuticals U.S.A., Inc. $0.7704/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955883239 CMS
ABBVIE INC. $19.4104/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893244857 CMS
Celgene Corporation $4.6504/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932546283 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.2304/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955883235 CMS
Janssen Biotech, Inc. $25.6504/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886733955 CMS
ABBVIE INC. $11.0203/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893244855 CMS
Celgene Corporation $11.7003/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932546265 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.0203/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959626725 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $2.3303/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959709483 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.5003/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955883231 CMS
Celgene Corporation $15.6102/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932546389 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.1702/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955883227 CMS
Janssen Biotech, Inc. $99.0002/18/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886733961 CMS
Janssen Biotech, Inc. $13.8402/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886734003 CMS
ABBVIE INC. $23.9802/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893244853 CMS
E.R. Squibb & Sons, L.L.C. $104.1102/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932546273 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.5002/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959384165 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $2.2502/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959772955 CMS
Takeda Pharmaceuticals U.S.A., Inc. $9.8302/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955883223 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.1401/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955883219 CMS
ABBVIE INC. $27.9801/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893244851 CMS
Celgene Corporation $14.7901/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932546387 CMS
Janssen Biotech, Inc. $22.7701/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886733997 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $739.10 30
PY2020 $677.77 26
PY2021 $1,082.95 47
PY2022 $1,885.69 81
PY2023 $3,011.15 112
PY2024 $4,631.41 116
PY2025 $3,767.76 122

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
Merged CMS profile IDs
274834, 577733

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,093,184.76 69
PY2024 Principal investigator $170,900.80 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

69 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $170.75 12/29/2025 Non-covered Recipient Entity
Bioluminix Clinical Research Illinois
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972543
Principal investigator 1 ModernaTX, Inc. $29,834.04 11/27/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972509
Principal investigator 1 ModernaTX, Inc. $8,345.04 11/27/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972521
Principal investigator 1 ModernaTX, Inc. $9,003.15 11/27/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972523
Principal investigator 1 ModernaTX, Inc. $273.20 11/19/2025 Non-covered Recipient Entity
Bioluminix Clinical Research Illinois
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972469
Principal investigator 1 ModernaTX, Inc. $2,334.15 10/27/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972465
Principal investigator 1 ModernaTX, Inc. $1,566.00 10/27/2025 Non-covered Recipient Entity
Bioluminix Clinical Research Illinois
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972493
Principal investigator 1 ModernaTX, Inc. $8,268.48 10/27/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972591
Principal investigator 1 SANOFI US SERVICES INC. $33,352.00 10/24/2025 Non-covered Recipient Entity
Bioluminux Clinical Research New Jersey
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype No dispute reported 06/30/2026 1226103863
Principal investigator 1 ModernaTX, Inc. $2,038.40 10/09/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972519
Principal investigator 1 ModernaTX, Inc. $3,648.00 10/09/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972527
Principal investigator 1 ModernaTX, Inc. $2,787.20 10/09/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972577
Principal investigator 1 ModernaTX, Inc. $12,671.10 09/29/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972479
Principal investigator 1 ModernaTX, Inc. $7,541.16 09/29/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972585
Principal investigator 1 ModernaTX, Inc. $30,292.08 08/28/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972533
Principal investigator 1 ModernaTX, Inc. $13,338.00 08/28/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972553
Principal investigator 1 ModernaTX, Inc. $8,383.32 08/28/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972563
Principal investigator 1 ModernaTX, Inc. $5,409.30 07/28/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972473
Principal investigator 1 ModernaTX, Inc. $2,143.68 07/28/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972507
Principal investigator 1 ModernaTX, Inc. $1,000.35 07/28/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972535
Principal investigator 1 ModernaTX, Inc. $7,573.02 06/27/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972513
Principal investigator 1 ModernaTX, Inc. $7,335.90 06/27/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972529
Principal investigator 1 ModernaTX, Inc. $6,258.78 06/27/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972575
Principal investigator 1 ModernaTX, Inc. $12,671.10 06/18/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972477
Principal investigator 1 ModernaTX, Inc. $792.87 06/18/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972491
Principal investigator 1 ModernaTX, Inc. $41,110.68 06/18/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972515
Principal investigator 1 ModernaTX, Inc. $7,388.04 06/18/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972547
Principal investigator 1 ModernaTX, Inc. $36,783.24 05/28/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972467
Principal investigator 1 ModernaTX, Inc. $7,923.96 05/28/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972499
Principal investigator 1 ModernaTX, Inc. $28,343.25 05/28/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972565
Principal investigator 1 ModernaTX, Inc. $15,087.54 05/07/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972551
Principal investigator 1 ModernaTX, Inc. $7,962.24 04/28/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972475
Principal investigator 1 ModernaTX, Inc. $36,679.50 04/28/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972561
Principal investigator 1 ModernaTX, Inc. $127.40 04/16/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972487
Principal investigator 1 ModernaTX, Inc. $70.20 04/16/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972489
Principal investigator 1 ModernaTX, Inc. $214.50 04/16/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972539
Principal investigator 1 ModernaTX, Inc. $4,574.70 04/16/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972573
Principal investigator 1 ModernaTX, Inc. $122.20 04/16/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972597
Principal investigator 1 ModernaTX, Inc. $1,392.30 04/11/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972485
Principal investigator 1 ModernaTX, Inc. $70.20 04/11/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972545
Principal investigator 1 ModernaTX, Inc. $122.20 04/11/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972555
Principal investigator 1 ModernaTX, Inc. $127.40 04/11/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972581
Principal investigator 1 ModernaTX, Inc. $29,877.12 03/24/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972525
Principal investigator 1 ModernaTX, Inc. $6,813.84 03/24/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972549
Principal investigator 1 ModernaTX, Inc. $30,677.40 03/24/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972567
Principal investigator 1 ModernaTX, Inc. $36,012.60 02/27/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972483
Principal investigator 1 ModernaTX, Inc. $792.87 02/27/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972505
Principal investigator 1 ModernaTX, Inc. $102.45 02/27/2025 Non-covered Recipient Entity
BIOLUMINIX CLINICAL RESEARCH ILLINOIS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972511
Principal investigator 1 ModernaTX, Inc. $8,689.56 02/27/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972557
Principal investigator 1 ModernaTX, Inc. $7,469.28 02/27/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972559
Principal investigator 1 ModernaTX, Inc. $99,158.15 02/27/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972571
Principal investigator 1 ModernaTX, Inc. $7,560.30 02/27/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972583
Principal investigator 1 ModernaTX, Inc. $25,608.96 01/30/2025 Non-covered Recipient Entity
BIOLUMINUXCLINICALRESEARCHILLINOISLLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972497
Principal investigator 1 ModernaTX, Inc. $842.16 01/30/2025 Non-covered Recipient Entity
BIOLUMINUXCLINICALRESEARCHILLINOISLLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972501
Principal investigator 1 ModernaTX, Inc. $9,595.95 01/30/2025 Non-covered Recipient Entity
BIOLUMINUXCLINICALRESEARCHILLINOISLLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972517
Principal investigator 1 ModernaTX, Inc. $7,789.75 01/30/2025 Non-covered Recipient Entity
BIOLUMINUXCLINICALRESEARCHILLINOISLLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972537
Principal investigator 1 ModernaTX, Inc. $792.87 01/30/2025 Non-covered Recipient Entity
BIOLUMINUXCLINICALRESEARCHILLINOISLLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972541
Principal investigator 1 ModernaTX, Inc. $11,670.75 01/30/2025 Non-covered Recipient Entity
BIOLUMINUXCLINICALRESEARCHILLINOISLLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972569
Principal investigator 1 ModernaTX, Inc. $9,818.24 01/30/2025 Non-covered Recipient Entity
BIOLUMINUXCLINICALRESEARCHILLINOISLLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972589
Principal investigator 1 ModernaTX, Inc. $3,062.40 01/30/2025 Non-covered Recipient Entity
BIOLUMINUXCLINICALRESEARCHILLINOISLLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972593
Principal investigator 1 ModernaTX, Inc. $37,390.80 01/21/2025 Non-covered Recipient Entity
BIOLUMINUXCLINICALRESEARCHILLINOISLLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972471
Principal investigator 1 ModernaTX, Inc. $100,636.96 01/21/2025 Non-covered Recipient Entity
BIOLUMINUXCLINICALRESEARCHILLINOISLLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972481
Principal investigator 1 ModernaTX, Inc. $15,465.12 01/21/2025 Non-covered Recipient Entity
BIOLUMINUXCLINICALRESEARCHILLINOISLLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972495
Principal investigator 1 ModernaTX, Inc. $1,585.74 01/21/2025 Non-covered Recipient Entity
BIOLUMINUXCLINICALRESEARCHILLINOISLLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972503
Principal investigator 1 ModernaTX, Inc. $59,754.24 01/21/2025 Non-covered Recipient Entity
BIOLUMINUXCLINICALRESEARCHILLINOISLLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972531
Principal investigator 1 ModernaTX, Inc. $26,676.00 01/21/2025 Non-covered Recipient Entity
BIOLUMINUXCLINICALRESEARCHILLINOISLLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972579
Principal investigator 1 ModernaTX, Inc. $6,067.38 01/21/2025 Non-covered Recipient Entity
BIOLUMINUXCLINICALRESEARCHILLINOISLLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972587
Principal investigator 1 ModernaTX, Inc. $15,993.25 01/21/2025 Non-covered Recipient Entity
BIOLUMINUXCLINICALRESEARCHILLINOISLLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252972595
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $128,150.00 01/02/2025 Non-covered Recipient Entity
BIOLUMINUX CLINICAL RESEARCH ILLINOIS
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER) No dispute reported 06/30/2026 1214124904